Alnylam Pharmaceuticals (ALNY) - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US02043Q1076
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that concentrates on creating innovative therapeutics through ribonucleic acid interference. The company has a variety of products in the market like ONPATTRO (patisiran) used to treat polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis. AMVUTTRA is designed for hATTR amyloidosis and polyneuropathy in adults; GIVLAARI for treating acute hepatic porphyria in adults; and OXLUMO for primary hyperoxaluria type 1.
Moreover, Alnylam Pharmaceuticals, Inc. is continuously developing new treatments such as patisiran and cemdisiran for different types of amyloidosis, Belcesiran and Elebsiran for liver diseases, Zilebesiran for hypertension, ALN-APP for Alzheimer's disease, ALN-HSD for NASH, and more. They also have products in the pipeline including Fitusiran for hemophilia, Inclisiran for hypercholesterolemia, lumasiran for advanced PH1, and vutrisiran for ATTR amyloidosis.
Alnylam Pharmaceuticals, Inc. has established strategic partnerships with Regeneron Pharmaceuticals, Inc. and Roche to collaborate on RNAi therapeutics targeting specific diseases in the eye and CNS as well as the development of pharmaceutical products. The company also collaborates with other industry leaders like Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc.
Founded in 2002, Alnylam Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. You can find more information about them on their website: https://www.alnylam.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
ALNY Stock Overview
Market Cap in USD | 18,100m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2004-05-28 |
ALNY Stock Ratings
Fundamental | -2.56 |
Dividend | - |
Growth 5y | 3.18 |
Rel. Performance vs Sector | -4.66 |
Analysts | 4.07/5 |
Fair Price Momentum | 158.51 USD |
Fair Price DCF | 9.13 USD |
ALNY Dividends
Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
ALNY Growth Ratios
Growth 12m | -23.71% |
Growth Correlation 12m | -57% |
Growth Correlation 3m | -79% |
CAGR 5y | 10.21% |
Sharpe Ratio 12m | -0.84 |
Alpha vs SP500 12m | -51.44 |
Beta vs SP500 5y weekly | 0.86 |
ValueRay RSI | 49.68 |
Volatility GJR Garch 1y | 46.36% |
Price / SMA 50 | -7.2% |
Price / SMA 200 | -15.76% |
Current Volume | 666.6k |
Average Volume 20d | 644.9k |
External Links for ALNY Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of March 29, 2024, the stock is trading at USD 149.45 with a total of 666,592 shares traded.
Over the past week, the price has changed by +1.93%, over one month by -3.72%, over three months by -23.64% and over the past year by -20.74%.
According to ValueRays Forecast Model, ALNY Alnylam Pharmaceuticals will be worth about 175.7 in March 2025. The stock is currently trading at 149.45. This means that the stock has a potential upside of +17.58%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 222.6 | 48.9% |
Analysts Target Price | 229.4 | 53.5% |
ValueRay Target Price | 175.7 | 17.6% |